Hanyu Pharmaceutical (300199.SZ): HY3003 tablets received drug clinical trial application accepted

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received the “Notice of Acceptance” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) regarding the clinical trial application for HY3003 tablets.

HY3003 tablets are a GLP-1R/GIPR/GCGR triple agonist oral formulation developed by the company. It is intended for use in indications such as weight loss, type 2 diabetes, and metabolism-related fatty hepatitis. It is a major innovative drug type in the company's layout in the field of metabolic diseases. The HY3003 project uses a multi-dosage parallel development strategy. The development direction includes HY3003 injection (weekly formulation), HY3003 extended-release injection (monthly formulation), and HY3003 tablets (once-daily oral formulation).